Compare Agilent Technologies Inc (A) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Xylem, Inc. — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Xylem, Inc. trades at $123.19 (market cap $28.30B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Xylem, Inc. pays the higher dividend (1.42%). Which is the better fit depends on your goals.
| A | XYL | |
|---|---|---|
Market Cap | $42.00B | $28.30B |
Sector | Health | Industrials |
52-Week High | $157.20 | $152.95 |
52-Week Low | $110.24 | $106.34 |
Enterprise Value | $43.55B | $30.08B |
Dividend Yield | 0.69% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Xylem (XYL) trades at $120.32, down 0.36% on the day, with a neutral technical signal and key support at $120. The company reported strong Q2 2026 earnings of $1.46 per share, beating estimates, and raised its full-year profit guidance. Revenue growth has been steady, reaching $9.04B in 2025, with net income margins improving to 10.59%. Analyst sentiment is mixed, with a consensus price target of $150.43, implying significant upside from current levels.
The outlook for XYL is positive, driven by robust demand in water technology and AI infrastructure, alongside margin expansion. Key risks include project delays in electric metering and competitive pressures. With a P/E of 28.65, the stock trades at a premium, but continued execution on earnings and strategic acquisitions supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
